Waystar Mulls Sale: Software Provider Eyes Return to Private Ownership

Waystar, a prominent healthcare software company specializing in automating administrative tasks for hospitals and doctors, is reportedly exploring strategic options, including a potential sale. According to sources familiar with the matter, the company has engaged investment bank Evercore to assist in this process. This move comes two years after Waystar's public listing on the New York Stock Exchange.

Market Pressures and Strategic Repositioning

The Lehi, Utah, and Louisville, Kentucky-based firm, which emerged from the 2017 merger of Zirmed and Navicure, has seen its market value decline to approximately $4.8 billion. This follows a 24% drop in its stock price amid a broader downturn in the software sector. Originally, Waystar aimed to distinguish itself as a technology company rather than a healthcare services provider, seeking higher valuations typically associated with tech firms. However, market dynamics, including concerns over artificial intelligence advancements potentially disrupting the software industry, have affected investor sentiment.

Key Stakeholders and Potential Outcomes

Waystar's largest shareholders include EQT with a 13% stake, followed by the Canada Pension Plan Investment Board (CPPIB) holding 10%, and BlackRock Institutional Trust Company at 8%. Neither EQT nor CPPIB responded to requests for comment, while BlackRock declined to comment on the matter. The company’s decision to explore a sale could test investor interest in software businesses amidst current market conditions. While the process is in its early stages and outcomes remain uncertain, it indicates a strategic evaluation of its public market performance and growth prospects.

Background and Market Context

Waystar initially saw its shares rise from $20 to a peak of $45 in 2025, driven by investor interest in its technology-focused business model. However, the recent selloff in the software industry has led to a reassessment of valuations. The company's decision to potentially return to private ownership highlights the shifting landscape for public software companies and the challenges they face in maintaining investor confidence.

As the situation develops, the outcome of Waystar's exploration could provide insights into the current appetite for healthcare technology investments and the broader implications for similar companies navigating the public markets.